AMELUZ: payments to doctors
Payments that named AMELUZ as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 8,312
- Transactions
- 24,550
- Average per transaction
- $50
The per-transaction average — $50 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,312 providers the average total is $147, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Biofrontera Inc. | $1,214,592 | 99.4% |
| Biofrontera Bioscience GmbH | $7,099 | 0.6% |